Unravelling the ties that bind: The intersection of obesity, osteoarthritis, and inflammatory pathways with emphasis on glucagon‐like peptide‐1 agonists

Documenti analoghi

• The role of glucagon‐like peptide 1 receptor agonists for weight control in individuals with acquired hypothalamic obesity—A systematic review
  di: Victoria Wen Wei Ng, et al.
  Pubblicazione: (2024)
• Effect of glucagon‐like peptide 1 receptor agonists on systolic blood pressure in patients with obesity, with or without diabetes: A systematic review and network meta‐analysis
  di: Abraish Ali, et al.
  Pubblicazione: (2025)
• Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States
  di: Yunwen Xu, et al.
  Pubblicazione: (2025)
• Impact of glucagon‐like peptide‐1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes
  di: Fu‐Shun Yen, et al.
  Pubblicazione: (2025)
• Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists
  di: David C. Klonoff, et al.
  Pubblicazione: (2024)